Cargando…
Successful Treatment of an Acute High-Dose Clozapine Poisoning without Detoxication
Patient: Male, 28-year-old Final Diagnosis: Clozapine poisoning Symptoms: Drowsiness • hyperventilation • impaired consciousness • respiratory insufficiency • tachycadia Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Psychiatry OBJECTIVE: Management of emergency care BACKGRO...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897594/ https://www.ncbi.nlm.nih.gov/pubmed/33591960 http://dx.doi.org/10.12659/AJCR.929147 |
Sumario: | Patient: Male, 28-year-old Final Diagnosis: Clozapine poisoning Symptoms: Drowsiness • hyperventilation • impaired consciousness • respiratory insufficiency • tachycadia Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Psychiatry OBJECTIVE: Management of emergency care BACKGROUND: Clozapine is a well-proven atypical antipsychotic drug used for therapy of treatment-resistant schizophrenia. Over the last decades only a few cases of clozapine poisoning have been reported. Hence, guidelines for inhospital management are currently not available. Most of the reported cases underwent detoxication measures as charcoal therapy and/or gastric lavage. However, there is no evidence for primary detoxication to improve clinical outcome. In contrast, use of therapy with intravenous physostigmine in the case of anticholinergic syndrome is restricted due to concerns about safety and dosing. We present a case of acute high-dose clozapine poisoning without detoxication and complete recovery supported by physostigmine. CASE REPORT: We report the case of a 28-year-old man with prior diagnosed schizophrenia who presumably ingested 8 g (regular maximum daily dose 900 mg/d) of clozapine with uncertain intent. Initial computed tomography (CT) showed pulmonary infiltrates and widespread pneumomediastinum and soft-tissue emphysema of unknown genesis. The patient developed a progressive impairment of vigilance and respiratory insufficiency requiring invasive artificial ventilation for 31 h. Afterwards, an anticholinergic syndrome led again to impaired vigilance, tachycardia, and hyperventilation. To avoid risks associated with artificial ventilation, we applied physostigmine. Subsequently, the anticholinergic syndrome and the pneumomediastinum completely regressed and no further artificial ventilation was needed. CONCLUSIONS: Based on the presumably ingested dosage, we present the likely highest reported nonfatal overdose of clozapine without detoxication. Additionally, we observed widespread pneumomediastinum as an uncommon complication. Our approach was to refrain from detoxication to minimize complications and to treat early with physostig-mine because of anticholinergic syndrome to minimize its impact and to avoid artificial ventilation due do vigilance impairment. |
---|